EUROIMMUN Launches Quantitative ELISA to Measure SARS-CoV-2 Antibodies Against Viral S1 Protein
Underscores importance of serological testing using the S1 subunit for worldwide seroprevalence and vaccine development WALTHAM, Mass.–(BUSINESS WIRE)–Nov. 9, 2020– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that EUROIMMUN, a PerkinElmer company, has launched the Anti-SARS-CoV-2 QuantiVacTM ELISA (IgG) to quantify IgG antibodies against the SARS-CoV-2 S1... Read more